Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 1997
Business Overview: The Company operates in three primary segments: CooperVision, Inc. (contact lenses and diagnostic instruments), CooperSurgical, Inc. (surgical instruments), and Hospital Group of America, Inc. (HGA) (psychiatric facilities and outpatient services).
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Net Operating Revenue | $28,376 | $22,249 |
| Income from Operations | $4,105 | $1,699 |
| Net Income | $3,310 | $652 |
| Earnings Per Share | $0.28 | $0.06 |
| Operating Cash Flow | $(2,252) | $(7,833) |
| Cash and Equivalents (End of Period) | $2,636 | $3,680 |
| Total Debt (Current + Long-term) | $49,980 | $48,764 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 28% ($6.1 million) driven by 26% growth in product sales and 31% growth in service revenue.
- Profitability Surge: Income from operations rose 142% ($2.4 million) to $4.1 million. Net income increased significantly due to operational improvements and a $290,000 tax benefit from reducing the deferred tax asset valuation allowance.
- Segment Performance:
- CooperVision: Sales up 21% due to strong growth in toric lenses (up 47%). Gross margin improved to 78%.
- CooperSurgical: Sales up 38% following the acquisition of Unimar products. Gross margin improved to 52%.
- HGA: Turned a $451k loss in Q1 1996 into a $667k profit in Q1 1997, aided by staff transitions at Hampton Hospital and cost controls.
- Cash Flow: Operating cash outflow improved by $5.5 million compared to the prior year, though the company still utilized $2.3 million in cash for operations, largely due to dispute settlements and bonus payments.
Guidance, Outlook, and Risks
- Fiscal 1997 Guidance: Management anticipates EPS between $1.55 and $1.65 (including a ~$0.15 deferred tax benefit). Consolidated revenue and operating income are projected to grow by more than 15% and 30%, respectively.
- Debt Redemption: The Company announced the redemption of $9.3 million in 10-5/8% Convertible Subordinated Reset Debentures on April 9, 1997. Holders may convert to common stock at $15/share or receive cash. Management expects this will not be dilutive to 1997 earnings.
- Acquisition Activity: A $1 million deposit was paid for the potential acquisition of the Natural Touch'r' contact lens line from Wesley-Jessen Corporation, pending FTC approval.
- Liquidity: The Company drew $1.5 million on its line of credit to fund operations and investing activities. Management expects positive operating cash flows for the remainder of fiscal 1997.
- Risks: Key risks include changes in managed care reimbursement rates, integration costs of acquisitions, regulatory delays, and competitive pressures.
Investor Verification Checklist
- Verify the outcome of the FTC approval for the Wesley-Jessen acquisition and the associated $1 million deposit status.
- Confirm the conversion rate vs. cash redemption election for the $9.3 million Debentures to assess potential dilution or cash outflow impact.
- Monitor HGA's ability to sustain double-digit growth amidst industry-wide pressures on psychiatric care reimbursement rates.
- Review the sustainability of CooperVision's margin expansion as it scales production volumes.
- Assess the Company's ability to generate positive operating cash flow in subsequent quarters to repay the line of credit without additional financing.